Бъбречни увреждания при редки генетични синдроми

Devuyst O, Knoers NV, Remuzzi G, Schaefer F; Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet. 2014 May 24;383(9931):1844-59. doi: 10.1016/S0140-6736(14)60659-0.

Паскалев Е. Справочник по нефрология, 2018, 309-320.

Pieroni M, Moon JC, Arbustini E et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Feb 23;77(7):922-936. doi: 10.1016/j.jacc.2020.12.024.

Vardarli I, Rischpler C, Herrmann K, Weidemann F. Diagnosis and Screening of Patients with Fabry Disease. Ther Clin Risk Manag. 2020 Jun 22;16:551-558. doi: 10.2147/TCRM.S247814.

Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA. 2000 Dec 6;284(21):2771-5. doi: 10.1001/jama.284.21.2771. Erratum in: JAMA 2001 Jan 10;285(2):169.

Zhang Y, Ding J. Renal, auricular, and ocular outcomes of Alport syndrome and their current management. Pediatr Nephrol. 2018 Aug;33(8):1309-1316.

Kashtan C. Alport syndrome: facts and opinions. F1000Res. 2017;6:50.

Boeckhaus J, Gale DP, Simon J, et al. SGLT2-Inhibition in Patients With Alport Syndrome. Kidney Int Rep. 2024 Sep 24;9(12):3490-3500. doi: 10.1016/j.ekir.2024.09.014.

Byrne MC, Budisavljevic MN, Fan Z, et al. Renal transplant in patients with Alport's syndrome. Am J Kidney Dis. 2002 Apr;39(4):769-75.

Kelberman D, Rizzoti K, Avilion A et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest. 2006;116:2442-2455.

Dattani MT, Robertson IC. HESX1 and septo-optic dysplasia. Rev Endocr Metab Disord. 2002;3:289-300.

Garne E, Rissmann A, Addor MC et al. Epidemiology of septo-optic dysplasia with focus on prevalence and maternal age – A EUROCAT study. Eur J Med Genet. 2018 Sep;61(9):483-488. doi: 10.1016/j.ejmg.2018.05.010. Epub 2018 May 10.

Barkovich AJ. Congenital malformations of the brain and skull. In: Barkovich AJ, ed. Pediatric neuroimaging, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:291-439.

Lane PH. Oligomeganephronia. In: eMedicine, consulted on July 5th 2017.

Khan OA, Majeed R, Saad M, et al. Rarity of Laurence Moon Bardet Biedl Syndrome and its poor management in the Pakistani population. Cureus. 2019;11:0.

Kumar A, Husain ASr, Saleem A et al. Laurence-Moon-Bardet-Biedl Syndrome: A Rare Case With a Literature Review. Cureus. 2020 Nov 5;12(11):e11355. doi: 10.7759/cureus.11355.

Forsyth RL, Gunay-Aygun M. GeneReviews®. Seattle: University of Washington; 2003. Bardet-Biedl syndrome overview.

Nadjmi B, Flanagan MJ, Christian JR. Laurence-Moon-Biedl Syndrome: Associated With Multiple Genitourinary Tract Anomalies. Am J Dis Child. 1969;117(3):352–356. doi:10.1001/archpedi.1969.02100030354022.

Hurley RM, Dery P, Norady MB, Drummond KN. The renal lesion of the Laurence-Moon-Biedl syndrome. J Pediatr. 1975 Aug;87(2):206-9. doi: 10.1016/s0022-3476(75)80580-4.

Marion V, Schlicht D, Mockel A et al. Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. Kidney Int 2011;79:1013-1025.

Regenbogen LS, Eliahou HE. Diseases Affecting the Eye and the Kidney, Karger, 1993.

Marion V, Schlicht D, Mockel A, et al. Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. Kidney Int 2011;79:1013-1025.

Zacchia M, Di Iorio V, Trepiccione F et al. The Kidney in Bardet-Biedl Syndrome: Possible Pathogenesis of Urine Concentrating Defect. Kidney Dis (Basel). 2017 Jul;3(2):57-65. doi: 10.1159/000475500. Epub 2017 May 17.

Koulouridis E, Koulouridis I. Molecular pathophysiology of Bartter‘s and Gitelman‘s syndromes. World J Pediatr. 2015 May;11(2):113-25. doi: 10.1007/s12519-015-0016-4. Epub 2015 Mar 9.

Konrad M, Nijenhuis T, Ariceta G et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int. 2021 Feb;99(2):324-335. doi: 10.1016/j.kint.2020.10.035.

Hené RJ, Koomans HA, Dorhout Mees EJ, et al. Correction of hypokalemia in Bartter’s syndrome by enalapril. Am J Kidney Dis. 1987 Mar;9(3):200-5. doi: 10.1016/s0272-6386(87)80055-0.

Nair N, Chakraborty R, Mahajan Z, et al. Renal Manifestations of Tuberous Sclerosis Complex. J Kidney Cancer VHL. 2020 Aug 27;7(3):5-19. doi: 10.15586/jkcvhl.2020.131. PMID: 32953421.

Rakowski SK, Winterkorn EB, Paul E, et al. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int. 2006;70(10):1777-82. doi: 10.1038/sj.ki.5001853.

Ewalt DH, Sheffield E, Sparagana SP, et al. Renal lesion growth in children with tuberous sclerosis complex. J Urol. 1998;160(1):141. doi: 10.1016/S0022-5347(01)63072-6.

Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002 Jul 11;347(2):111-21.

Servais A, Morinière V, Grünfeld JP, et al. Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. Clin J Am Soc Nephrol. 2008 Jan;3(1):27-35.

Bäumner S, Weber LT. Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease. Front Pediatr. 2018 Mar 14;6:58. doi: 10.3389/fped.2018.00058.

Brodin-Sartorius A, Tête MJ, Niaudet P, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int. 2012 Jan;81(2):179-89.

Levtchenko E, Servais A, Hulton SA, et al. Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients. Clin Kidney J. 2022 Apr 15;15(9):1675-1684. doi: 10.1093/ckj/sfac099.

Salomon R, Benmerah A, Heidet L et al. INSERM–Necker Hospital NPH collaborative group. The genetic landscape and clinical spectrum of nephronophthisis and related ciliopathies. Kidney Int. 2023 Aug;104(2):378-387. doi: 10.1016/j.kint.2023.05.007. Epub 2023 May 23.

Madjova V. Possibilities for early diagnosis of chronic kidney disease in outpatient settings, General Medicine, 2011, 13, 3-6.